Technical Analysis for MGNX - MacroGenics, Inc.

Grade Last Price % Change Price Change
A 34.515 2.54% 0.86
MGNX closed down 0.12 percent on Thursday, April 22, 2021, on 85 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bulls were able to push the stock to a new 52-week high. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Earnings due: May 3
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical MGNX trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 2.54%
NR7 Range Contraction 2.54%
Doji - Bearish? Reversal 2.54%
New 52 Week High Strength 2.54%
Upper Bollinger Band Walk Strength 2.54%
BB Squeeze Started Range Contraction 2.54%
BB Squeeze + Upper Band Touch Range Contraction 2.54%
Overbought Stochastic Strength 2.54%
Upper Bollinger Band Touch Strength 2.54%
New 52 Week Closing High Bullish 2.42%
Older End-of-Day Signals for MGNX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High 1 minute ago
New 52 Week High 1 minute ago
Rose Above Upper Bollinger Band 1 minute ago
Up 3% 1 minute ago
Up 2% 1 minute ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

MacroGenics, Inc. Description

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The company creates both differentiated molecules that are directed to novel cancer targets, as well as "bio-betters," which are drugs designed to improve upon marketed medicines. The combination of MacroGenics' technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Cancer Life Sciences Biology Immunology Immune System Treatment Of Cancer Antibodies Autoimmune Diseases Monoclonal Antibody Monoclonal Antibodies Autoimmune Disease Antibody Novel Cancer

Is MGNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 34.295
52 Week Low 6.51
Average Volume 816,649
200-Day Moving Average 25.32
50-Day Moving Average 27.92
20-Day Moving Average 31.99
10-Day Moving Average 31.94
Average True Range 1.79
ADX 20.89
+DI 23.75
-DI 14.27
Chandelier Exit (Long, 3 ATRs ) 28.93
Chandelier Exit (Short, 3 ATRs ) 33.92
Upper Bollinger Band 34.16
Lower Bollinger Band 29.82
Percent B (%b) 0.88
BandWidth 13.55
MACD Line 1.23
MACD Signal Line 1.24
MACD Histogram -0.0077
Fundamentals Value
Market Cap 1.89 Billion
Num Shares 56.2 Million
EPS -3.47
Price-to-Earnings (P/E) Ratio -9.69
Price-to-Sales 14.78
Price-to-Book 4.35
PEG Ratio 0.01
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 35.45
Resistance 3 (R3) 35.46 34.88 35.15
Resistance 2 (R2) 34.88 34.42 34.87 35.05
Resistance 1 (R1) 34.27 34.14 33.98 34.26 34.95
Pivot Point 33.69 33.69 33.54 33.68 33.69
Support 1 (S1) 33.08 33.23 32.79 33.06 32.37
Support 2 (S2) 32.49 32.95 32.49 32.27
Support 3 (S3) 31.89 32.49 32.17
Support 4 (S4) 31.87